GSK is redesigning pharmaceutical research around AI, from data infrastructure to autonomous scientific agents. Its platforms ...

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk: London, UK Tuesday, May 19, 2026, 12:00 Hrs [IST] GSK plc announced tha ...

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its ...

GSK has signed a new three-year agreement with Protas that aims to streamline trials across several core therapeutic areas.

Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-quarter earnings season.

GSK has disclosed a series of routine share dealings by senior executives under its Share Reward Plan, with ordinary shares acquired on 12 May 2026 on the London Stock Exchange. Participants include ...

CTTQ will manage importation, distribution, hospital access, and all promotional and non-promotional activities for bepirovirsen.

GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...

GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about ...

AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.

The agreement with Sino Bio, via its subsidiary Chia Tai Tianqing Pharma (CTTQ), allies GSK with a company that is one of ...

By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...